Dual signal activation carrier and method

By designing a dual-signal activation vector, NK cells are activated through covalent coupling of pimova serine phosphate with cytokines, which solves the problems of low NK cell expansion efficiency and metabolic function defects, achieving efficient expansion and functional enhancement of NK cells, making it suitable for clinical application.

CN122163827APending Publication Date: 2026-06-09JINAN WANQUAN BIOTECHNOLOGY CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202610636174.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-05-11
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

Existing NK cell activation technologies suffer from low efficiency, metabolic defects, and issues with bioavailability and safety, resulting in inefficient NK cell proliferation and poor function.

Method used

Using a dual-signal activation vector, pimova serin phosphate is covalently coupled to cytokines onto a biodegradable vector, activating the cGAS-STING pathway and the synergistic effect of cytokines, mimicking the immune activation pattern under physiological conditions, and promoting the efficient expansion and functional enhancement of NK cells.

Benefits of technology

It achieves efficient expansion of NK cells, enhances immune activation, solves the problem of functional inhibition in the tumor microenvironment, avoids cell depletion and systemic toxicity, and is suitable for clinical translation and large-scale industrialization.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122163827A_ABST
    Figure CN122163827A_ABST
Patent Text Reader

Abstract

The application provides a double-signal activated carrier and method, and belongs to the technical field of immune cells. In the application, a heterocyclic small molecule, pimovanel phosphate, is used as a cGAS-STING pathway agonist, and is covalently coupled to a biodegradable carrier together with a cytokine. The innate immune activation characteristics of the cGAS-STING pathway and the proliferation regulation characteristics of the cytokine are used to form synergy, to simulate the immune activation mode in a physiological state, to activate the cGAS-STING / IRF3 / NF-kappa B immune pathway and the SIRT7-PGC-1alpha metabolic pathway, to promote glycolysis and mitochondrial biosynthesis, and finally to realize efficient expansion, enhanced efficacy and persistent improvement of NK cells.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Method for safely preparing pimavanserin and tartrate thereof by utilizing triphosgene

    CN108947891A

  • Immunomodulation of myeloid-derived suppressor cell function for cancer treatment

    CN116322702A

  • Targeted STING pathway for preparing therapeutic NK cells

    CN116987666A

  • Large-scale culture method of NK (Natural Killer) cells and adopted culture medium

    CN119286781A

  • Method of treating alzheimer's disease with expanded natural killer cells

    WO2024238387A1